FDA approves wearable infusion device for advanced Parkinson disease
The U.S. Food and Drug Administration has approved Onapgo (apomorphine hydrochloride) injection as the first and only ...
drugdeliverybusiness2 天
Koru Medical inks deal to develop next-gen subcutaneous infusion system
Systems (Nasdaq:KRMD) announced today that it signed a development agreement with a global pharmaceutical company.
Koru announces pact for next-gen subcutaneous immunoglobulin infusion system
Systems announced the signing of an agreement with a global pharmaceutical company. The agreement is intended for KORU ...
The American Journal of Managed Care5 天
FDA Approves First Subcutaneous Apomorphine Device for Parkinson Disease
The FDA has approved the first and only subcutaneous apomorphine infusion device, apomorphine hydrochloride injection (Onapgo ...
Business Wire3 天
KORU Medical Systems Announces Agreement for Next-Generation Subcutaneous Immunoglobulin ...
The agreement is intended for KORU Medical to develop and seek regulatory clearance for a next-generation subcutaneous immunoglobulin (SCIg) therapy infusion system for use with a commercialized ...
MedPage Today5 天
FDA OKs New Wearable Treatment for Parkinson's Disease
The FDA approved an apomorphine hydrochloride infusion device (Onapgo) to treat motor fluctuations in adults with advanced ...
Pharm Exec2 天
FDA Approves Supernus Pharmaceuticals’ Onapgo for Managing Motor Fluctuations in ...
Approval of Onapgo (apomorphine hydrochloride) marks the first and only subcutaneous apomorphine infusion device for managing ...
KORU Medical Systems Announces Agreement for Next-Generation Subcutaneous Immunoglobulin ...
KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and ...